Massive diabetes drug study probes cancer link
NCT ID NCT02695121
First seen Apr 19, 2026 · Last updated May 08, 2026 · Updated 2 times
Summary
This study analyzed health records from over 2 million people with type 2 diabetes to see if those taking the drug dapagliflozin had a different risk of developing breast or bladder cancer compared to those on other diabetes medications. Researchers followed participants for up to 12 years. The goal was to gather information about safety, not to treat or cure any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Wilmington, Delaware, United States
-
Research Site
Washington D.C., District of Columbia, United States
-
Research Site
Utrecht, Netherlands
-
Research Site
London, United Kingdom
Conditions
Explore the condition pages connected to this study.